These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 35478219)

  • 1. A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition.
    Heilmann E; Costacurta F; Geley S; Mogadashi SA; Volland A; Rupp B; Harris RS; von Laer D
    Commun Biol; 2022 Apr; 5(1):391. PubMed ID: 35478219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination].
    Reina J; Iglesias C
    Rev Esp Quimioter; 2022 Jun; 35(3):236-240. PubMed ID: 35183067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mass Spectrometric Assays Reveal Discrepancies in Inhibition Profiles for the SARS-CoV-2 Papain-Like Protease.
    Brewitz L; Kamps JJAG; Lukacik P; Strain-Damerell C; Zhao Y; Tumber A; Malla TR; Orville AM; Walsh MA; Schofield CJ
    ChemMedChem; 2022 May; 17(9):e202200016. PubMed ID: 35085423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Biosafety Level 1 Cellular Assay for Identifying Small-Molecule Antivirals Targeting the Main Protease of SARS-CoV-2: Evaluation of Cellular Activity of GC376, Boceprevir, Carmofur, Ebselen, and Selenoneine.
    Fukumoto Y; Suzuki N; Hara R; Tanaka YK; Ogra Y
    Int J Mol Sci; 2024 May; 25(11):. PubMed ID: 38891954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Orthogonal dual reporter-based gain-of-signal assay for probing SARS-CoV-2 3CL protease activity in living cells: inhibitor identification and mutation investigation.
    Bei ZC; Yu H; Wang H; Li Q; Wang B; Zhang D; Xu L; Zhao L; Dong S; Song Y
    Emerg Microbes Infect; 2023 Dec; 12(1):2211688. PubMed ID: 37144395
    [No Abstract]   [Full Text] [Related]  

  • 7. Structural insights into Nirmatrelvir (PF-07321332)-3C-like SARS-CoV-2 protease complexation: a ligand Gaussian accelerated molecular dynamics study.
    Wang YT; Liao JM; Lin WW; Li CC; Huang BC; Cheng TL; Chen TC
    Phys Chem Chem Phys; 2022 Sep; 24(37):22898-22904. PubMed ID: 36124909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stabilization of the Dimeric State of SARS-CoV-2 Main Protease by GC376 and Nirmatrelvir.
    Paciaroni A; Libera V; Ripanti F; Orecchini A; Petrillo C; Francisci D; Schiaroli E; Sabbatini S; Gidari A; Bianconi E; Macchiarulo A; Hussain R; Silvestrini L; Moretti P; Belhaj N; Vercelli M; Roque Y; Mariani P; Comez L; Spinozzi F
    Int J Mol Sci; 2023 Mar; 24(7):. PubMed ID: 37047038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potent and effective SARS-CoV-2 main protease inhibitors based on maleimide analogs for the potential treatment of COVID-19.
    Biernacki K; Ciupak O; Daśko M; Rachon J; Flis D; Budka J; Inkielewicz-Stępniak I; Czaja A; Rak J; Demkowicz S
    J Enzyme Inhib Med Chem; 2024 Dec; 39(1):2290910. PubMed ID: 38093611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A highly sensitive cell-based luciferase assay for high-throughput automated screening of SARS-CoV-2 nsp5/3CLpro inhibitors.
    Chen KY; Krischuns T; Varga LO; Harigua-Souiai E; Paisant S; Zettor A; Chiaravalli J; Delpal A; Courtney D; O'Brien A; Baker SC; Decroly E; Isel C; Agou F; Jacob Y; Blondel A; Naffakh N
    Antiviral Res; 2022 May; 201():105272. PubMed ID: 35278581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gain-of-Signal Assays for Probing Inhibition of SARS-CoV-2 M
    Moghadasi SA; Esler MA; Otsuka Y; Becker JT; Moraes SN; Anderson CB; Chamakuri S; Belica C; Wick C; Harki DA; Young DW; Scampavia L; Spicer TP; Shi K; Aihara H; Brown WL; Harris RS
    mBio; 2022 Jun; 13(3):e0078422. PubMed ID: 35471084
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substitutions in SARS-CoV-2 Mpro Selected by Protease Inhibitor Boceprevir Confer Resistance to Nirmatrelvir.
    Gammeltoft KA; Zhou Y; Ryberg LA; Pham LV; Binderup A; Hernandez CRD; Offersgaard A; Fahnøe U; Peters GHJ; Ramirez S; Bukh J; Gottwein JM
    Viruses; 2023 Sep; 15(9):. PubMed ID: 37766376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural basis for the in vitro efficacy of nirmatrelvir against SARS-CoV-2 variants.
    Greasley SE; Noell S; Plotnikova O; Ferre R; Liu W; Bolanos B; Fennell K; Nicki J; Craig T; Zhu Y; Stewart AE; Steppan CM
    J Biol Chem; 2022 Jun; 298(6):101972. PubMed ID: 35461811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crystal structure of SARS-CoV-2 main protease in complex with protease inhibitor PF-07321332.
    Zhao Y; Fang C; Zhang Q; Zhang R; Zhao X; Duan Y; Wang H; Zhu Y; Feng L; Zhao J; Shao M; Yang X; Zhang L; Peng C; Yang K; Ma D; Rao Z; Yang H
    Protein Cell; 2022 Sep; 13(9):689-693. PubMed ID: 34687004
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of the Inhibition Potency of Nirmatrelvir against Main Protease Mutants of SARS-CoV-2 Variants.
    Jiang H; Zhou Y; Zou X; Hu X; Wang J; Zeng P; Li W; Zeng X; Zhang J; Li J
    Biochemistry; 2023 Jul; 62(13):2055-2064. PubMed ID: 37222536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Substitutions L50F, E166A, and L167F in SARS-CoV-2 3CLpro Are Selected by a Protease Inhibitor
    Jochmans D; Liu C; Donckers K; Stoycheva A; Boland S; Stevens SK; De Vita C; Vanmechelen B; Maes P; Trüeb B; Ebert N; Thiel V; De Jonghe S; Vangeel L; Bardiot D; Jekle A; Blatt LM; Beigelman L; Symons JA; Raboisson P; Chaltin P; Marchand A; Neyts J; Deval J; Vandyck K
    mBio; 2023 Feb; 14(1):e0281522. PubMed ID: 36625640
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supervised Molecular Dynamics (SuMD) Insights into the mechanism of action of SARS-CoV-2 main protease inhibitor PF-07321332.
    Pavan M; Bolcato G; Bassani D; Sturlese M; Moro S
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1646-1650. PubMed ID: 34289752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ferrocenoyl-substituted quinolinone and coumarin as organometallic inhibitors of SARS-CoV-2 3CLpro main protease.
    Graf D; Farn N; Klopf J; Hojjati M; Schatzschneider U
    Metallomics; 2023 May; 15(5):. PubMed ID: 37070961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of M Protease Inhibitors Encoded by SARS-CoV-2.
    Hung HC; Ke YY; Huang SY; Huang PN; Kung YA; Chang TY; Yen KJ; Peng TT; Chang SE; Huang CT; Tsai YR; Wu SH; Lee SJ; Lin JH; Liu BS; Sung WC; Shih SR; Chen CT; Hsu JT
    Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32669265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.